Physician profile
Ralph G Nader
NPI 1023011970
$6,777.66
in general payments reported to CMS, 2019-2025
25 companies · $410 in 2025
The $410 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,743 · 2020: $1,024 · 2021: $757 · 2022: $534 · 2023: $913 · 2024: $1,396 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,719.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,078.53 | 2019-2023 | Gallant, Aveir, Assurity |
| Medtronic, INC. | $1,423.55 | 2022-2025 | Micra, Mycarelink, Pulseselect |
| Sanofi-Aventis U.S. LLC | $518.68 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $320.03 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $308.30 | 2019-2025 | Wainua |
| Edwards Lifesciences Corporation | $264.84 | 2024 | |
| Janssen Pharmaceuticals, INC | $261.50 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $252.44 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $206.80 | 2019-2025 | |
| Boston Scientific Corporation | $192.23 | 2024 | Watchman Flx |
| Atricure, INC. | $177.77 | 2021 | |
| Comsort, INC | $150.00 | 2019 | |
| Amgen INC. | $134.31 | 2023-2025 | Repatha, Repatha |
| Kowa Pharmaceuticals America, INC. | $117.74 | 2019-2021 | |
| Pfizer INC. | $74.39 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.49 | 2024 | Jardiance |
| Arbor Pharmaceuticals, INC. | $43.47 | 2019 | |
| Bridgebio Pharma, INC. | $32.45 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $28.32 | 2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $27.71 | 2019 | |
| Novo Nordisk INC | $24.88 | 2025 | Ozempic |
| Kestra Medical Technology Services, INC. | $24.06 | 2024 | Assure Wcd |
| Dendreon Pharmaceuticals LLC | $21.63 | 2019 | |
| Sanofi Pasteur INC. | $20.83 | 2019 | |
| Heartflow, INC. | $18.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Nader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.